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Background: Leishmaniasis is a globally important yet neglected 
parasitic disease transmitted by phlebotomine sand flies. With new 
candidate vaccines in or near the clinic, a controlled human challenge 
model (CHIM) using natural sand fly challenge would provide a 
method for early evaluation of prophylactic efficacy. 
Methods: We evaluated the biting frequency and adverse effects 
resulting from exposure of human volunteers to bites of either 
Phlebotomus papatasi or P. duboscqi, two natural vectors of Leishmania 
major. 12 healthy participants were recruited (mean age 40.2 ± 11.8 
years) with no history of significant travel to regions where L. major-
transmitting sand flies are prevalent. Participants were assigned to 
either vector by 1:1 allocation and exposed to five female sand flies for 
30 minutes in a custom biting chamber. Bite frequency was recorded 
to confirm a bloodmeal was taken. Participant responses and safety 
outcomes were monitored using a visual analogue scale (VAS), clinical 
examination, and blood biochemistry. Focus groups were 
subsequently conducted to explore participant acceptability.  
Results: All participants had at least one successful sand fly bite with 
none reporting any serious adverse events, with median VAS scores of 
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0-1/10 out to day 21 post-sand fly bite. Corresponding assessment of 
sand flies confirmed that for each participant at least 1/5 sand flies 
had successfully taken a bloodmeal (overall mean 3.67±1.03 bites per 
participant). There was no significant difference between P. papatasi 
and P. duboscqi in the number of bites resulting from 5 sand flies 
applied to human participants (3.3±0.81 vs 3.00±1.27 bites per 
participant; p=0.56).  In the two focus groups (n=5 per group), themes 
relating to positive participant-reported experiences of being bitten 
and the overall study, were identified. 
Conclusions: These results validate a protocol for achieving successful 
sand fly bites in humans that is safe, well-tolerated and acceptable for 
participants. 
Clinicaltrials.gov registration: NCT03999970 (27/06/2019)
Keywords 
Controlled human infection models; leishmaniasis, vaccines, sand 
flies; public engagement, focus groups
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Introduction
The World Health Organisation (WHO) has identified several 
neglected tropical diseases postulated to be vaccine preventable 
but where progress in vaccine development has been limited1. 
Included amongst these are the leishmaniases, a group of dis-
eases caused by different species of Leishmania parasites that 
affect over 100 million people across 98 countries2,3, with an 
estimated 1 billion living in endemic areas at risk of infection 
worldwide4,5. Although the majority of cases of leishmania-
sis affect the skin (the tegumentary leishmaniases, including 
localised cutaneous leishmaniasis, mucosal leishmaniasis, dif-
fuse cutaneous leishmaniasis, disseminated cutaneous leishma-
niasis and post kala azar dermal leishmaniasis), some species 
of Leishmania cause visceral leishmaniasis (VL or kala azar) 
affecting the internal organs and leading to death if untreated. 
Up to 18,700 deaths from VL occurred in 2019, a reduction 
from past decades that is in part attributed to the ongoing 
elimination campaign in South Asia4,6,7. Phlebotomine sand 
flies (Diptera: Phlebotominae), mostly belonging to the gen-
era Phlebotomus and Lutzomyia, are biological vectors of 
Leishmania, and some exhibit close evolutionary relationships 
with specific Leishmania species8,9.
Significant challenges in leishmaniasis control remain includ-
ing a lack of effective treatments and drug resistance10, a poor 
understanding of infection reservoir dynamics11,12 and the lim-
ited impact of vector control programmes13. The availability of 
an effective vaccine would have a major impact on health and 
economic development in low-and-middle income countries 
(LMICs) where leishmaniasis is endemic, particularly on 
transmission and population incidence, as well as potentially 
leading to elimination14. To-date no human vaccine for leish-
maniasis has been licensed, although several vaccines are being 
developed15–17. Numerous barriers limit the development of 
such vaccines, including resource allocation to leishmania-
sis research, limited translational application of animal models, 
and lack of effective correlates of protection.
For several diseases where there is an urgent need for a vac-
cine, controlled human infection models (CHIM) have been 
proposed as a mechanism for efficiently and cost-effectively 
evaluating new vaccines and therapies18,19. In such models, 
healthy participants are deliberately infected with the patho-
gen of interest and at the end of the observation period, inter-
ventions are used to curtail the infection. Over the last half 
century, structured evidenced-based and ethical approaches to 
CHIM studies have gained traction. CHIM models have 
been developed for a range of viral, bacterial, protozoan and 
helminth diseases20, including malaria18, influenza21, norovirus22, 
dengue23, Streptococcus pneumoniae24 and schistosomiasis25. 
More recently CHIM studies have been proposed as a means of 
testing potential severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) vaccines in order to control the coronavirus 
disease 2019 (COVID-19) pandemic26,27. In some CHIM stud-
ies, including with malaria vaccines18, the natural vector 
has been used to facilitate infection, and this may be particu-
larly important when the process of vector transmission facili-
tates infection or alters immune responses in a manner not 
mimicked by needle challenge28–30.
Multiple arguments support the notion that the leishmaniases 
are vaccine preventable diseases including demonstrable immu-
nity following infection and self-cure16,31. “Leishmanization” 
in areas endemic for cutaneous leishmaniasis involved the 
inoculation of live virulent parasites into cosmetically less 
conspicuous areas, typically on the buttock, to prevent subse-
quent lesion development at more stigmatizing sites. Whilst a 
testament to the ability of prior infection to generate protec-
tive immunity, this practice was discouraged due to ethical 
concerns32,33. Leishmanization nevertheless provided the basis 
for a proof of concept Leishmania CHIM in Iran, conducted 
in 2005, that demonstrated using needle challenge, that a 
reasonable take rate, self-healing of lesions and subse-
quent protection could be achieved using parasites expanded 
under GMP conditions32,33. This approach, however, was not 
pursued further. The development of new candidate vac-
cines for leishmaniasis, in34–36 or near to clinical trial37–39, pro-
vides the impetus to re-evaluate and update the previous CHIM 
model. Recent findings that broaden the understanding of 
the challenges of a Leishmania CHIM are also an important 
consideration, including the importance of vector-derived 
factors that includes sand fly saliva40 and microbiota29, and 
parasite by-products such as the promastigote secretory gel41, 
exosomes42 and other virulence factors43, that have the 
potential to modify and impact vaccine efficacy44.
A proviso for a vector transmitted leishmaniasis CHIM is to 
have an efficient protocol to allow sand flies to safely bite 
human volunteers. Previous studies45–47 have demonstrated that 
controlled sand fly biting on humans is achievable and a pro-
tocol to examine human immune responses following sand 
fly bite has recently been developed48. The specific aims of 
the current study are to assess the biting frequency and pro-
portion of P. papatasi and P. duboscqi females success-
fully taking a blood meal when exposed to human skin and to 
record adverse events through clinical examination including 
dermatoscopy, evaluation of routine biochemistry and the 
use of a visual analogue scale assessing severity of signs and 
symptoms. In addition, following a previous public involve-
ment (PI) consultation group exercise49, that was used to 
shape the current protocol, we conducted a follow-up focus 
group with volunteers to record their attitudes and experi-
ences of the FLYBITE study, and to help refine the devel-
opment of a cutaneous leishmaniasis CHIM. This study is 




The study was approved by the UK National Health Service 
Research Ethics Committee on the 2nd August 2019 (Refer-
ence: 19/SC/0297; project ID 266151); and by the Department 
of Biology Ethics Committee, University of York on the 9th 
September 2019 (CL201908). The study was registered at 
www.clinicaltrials.gov (NCT03999970) on the 27th June 201951. 
Study design
The study was conducted in the Translational Research Facility 
at the University of York, UK and was a non-randomised, 
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participant-blinded clinical study in healthy participants with 
two parallel arms and a 1:1 allocation. In total, 12 partici-
pants were recruited to two study groups, one group exposed to 
P. papatasi and one exposed to P. duboscqi. Sample size was 
based on a number of factors including the sample size used 
in similar CHIM studies in the development of new models, 
for example in the pilot CHIM studies for malaria52,53. In these 
models, 4 and 5 participants were recruited respectively. 
Previous data suggests the take rate for Leishmania in a con-
trolled setting is 82.6%32, in comparison to the higher take rate 
in the more efficient malaria model. Therefore in our model 
using two sand fly species, we determined that enrolling 6 
participants per species was the most appropriate number to 
balance safety and efficacy. Recruitment was via advertise-
ment within the University of York as well as local media, and 
both internal and external websites54. The participants were 
allocated to each group based on availability of sand flies 
without randomisation. The study was conducted according to 
the principles of the current revision of the Declaration of Hel-
sinki 2008 and ICH guidelines for GCP (CPMP/ICH/135/95). 
All participants provided written informed consent for the 
sand fly biting study and the focus groups prior to enrolment.
Participants were compensated for their time and inconven-
ience at the following rates in relation to each visit: screening 
visit, £60; sand fly biting visit, £100; 3 follow-up visits, £25 
per visit; focus group, £60.
Outcome measures
The primary outcome measure was safety and effectiveness of 
the sand fly biting protocol, with effectiveness being defined 
as the number of sand fly bites sustained (Extended Data 150). 
Effectiveness was assessed by visualisation of sand fly bites 
immediately after the biting procedure, participant reported 
biting sensation and investigator-reported sand fly engorge-
ment. Clinically visible evidence of bites following removal of 
the sand fly biting chamber were identified using dermoscopy 
and digital photography and the bites then counted. These 
counts were verified by two study researchers. A propor-
tion of these images were later checked by study clinicians to 
ensure accuracy and consistency. Safety was assessed by 
adverse event data collection through clinical history, clini-
cal examination & blood testing, as well as participant-reported 
experience from diary card data.
The secondary outcome measures were the recorded response 
to sand fly bite on human participants, and participant’s 
attitudes to sand fly biting. Human response was measured 
by clinical photography and dermoscopy, a routine blood 
panel including inflammatory markers, total immunoglobu-
lin E (IgE), and the development of antibody responses to sand 
fly salivary gland proteins. A post-study focus group with study 
participants was undertaken to determine their experiences 
of taking part in the research.
Eligibility criteria
Healthy male and female subjects aged between 18 and 
65 years old were eligible. Participants were screened for poten-
tial immunodeficiencies based on blood-borne virus testing 
and full blood count, as well as clinical examination and 
clinical history. Participants were excluded if they had a past 
history of leishmaniasis (determined by rK39 Leishmania 
antibody rapid diagnostic test (IT LEISH, Bio-Rad)), had 
received recent immunizations, immunoglobins or blood prod-
ucts that could interfere with any serological analysis, any his-
tory of significant skin conditions, atopy, anaphylaxis or other 
serious reactions including significantly raised IgE at baseline. 
IgE was measured given the ease of processing in compari-
son to serum tryptase, and its relationship with active atopic 
diseases55, and the subsequent relationship between atopy 
and anaphylaxis56. The risk of previous Leishmania infection 
undetectable by serology and sand fly exposure was assessed 
and any participants with recent or prolonged history of 
travel to regions where Leishmania-transmitting sand flies 
are endemic were excluded. Inclusion criteria included willing-
ness to give consent to refrain from travel to L. major-endemic 
regions during the study.
Maintenance of sand flies
P. papatasi and P. duboscqi sand flies were obtained from 
a colony maintained at Charles University, Prague. The col-
ony is reared based on extensive experience and consensus 
on sand fly rearing57,58. Colonies were routinely screened for 
Phleboviruses and Flaviviruses. Sand flies were trans-
ported to a secure insectary at the University of York between 
days 3 to 5 of reaching the adult stage of development as 
holometabolous insects. Sand flies were maintained at 26°C 
and 70% humidity with a photoperiod of 12 hours light and 
12 hours dark, within 40cm2 nylon insect cages with a feeding 
membrane window (BugDorm, MegaView Science Co., Ltd., 
Taiwan). Sand flies were maintained on a sucrose solution 
between blood feeding (comprised of cotton wool soaked in a 
50% sucrose solution) and starved 18 to 25 hours before a 
blood meal at age 5 to 7 days. A rabbit blood meal was pro-
vided via a membrane (Hemotek membrane feeding system) for 
up to 1 hour in the dark59 before engorged females were sepa-
rated. Male sand flies were present during feeding to increase 
the rate of feeding58.
Preparation of the biting chamber
On the day of the clinical study, five female sand flies were 
placed into a custom-built watch-like biting chamber (Preci-
sion Plastics Inc, Maryland, USA). This occurred 12 to 15 days 
post-blood meal, at which point sand flies were aged 18 to 
21 days. All pre-biting procedures were conducted on ice to 
reduce sand fly metabolic activity60.
Study procedures and intervention
Pre -screening visit. All potential subjects had a pre-screen-
ing assessment conducted by either a clinician or study nurse 
either face-to-face or via telephone to determine eligibility and 
availability. This included general health status, allergy his-
tory, and any history of leishmaniasis infection or prolonged 
residence in an area where Leishmania-transmitting sand flies 
are endemic.
Screening visit. Screening visits were conducted by clini-
cal study investigators from 30 to 7 days prior to the sand fly 
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biting visit. After written informed consent, the subjects 
underwent a full medical history and clinical examination. 
A routine panel of blood samples were provided for haema-
tology, renal and liver function and C-reactive protein (CRP). 
A blood-borne virus screen (Hepatitis B surface antigen, HIV 
antibodies, Hepatitis C antibodies), serum β-Human Chorionic 
Gonadotropin for female participants and an rK39 Leishma-
nia antibody rapid diagnostic test (IT LEISH, Bio-Rad) was also 
carried out. Further blood samples were taken for downstream 
experimental and exploratory analysis including peripheral 
blood mononuclear cells (PBMCs) and testing for sero-evolution 
using an ELISA assay for antibodies to sand fly salivary 
proteins as described elsewhere61,62.
Sand fly biting visit. Up to two participants underwent sand 
fly biting on any given day, and no participants underwent 
sand fly biting simultaneously. Participants were provided with 
a neutral, non-scented skin wash to minimise any host fac-
tors that could account for variation in inter-participant sand 
fly biting behaviour63–65. Either P. papatasi or P. duboscqi were 
used depending on availability on the day of sand fly biting. 
The biting chamber with sand flies enclosed within was placed 
on the volar aspect of the non-dominant proximal forearm, 
approximately 2 to 3 centimetres distal to the antecubital 
fossa. The sand fly biting chambers were secured on the par-
ticipants arm for 30 minutes. The subjective experience of each 
participant to biting was recorded including biting sensation, 
pain and pruritis. A clinician and a research nurse observed 
the participant during this period.
Although there is no clear consensus or guidelines on the emer-
gency provisions needed during such a clinical study, after 
review of the literature the study investigators ensured that 
there was availability of appropriate resuscitation equipment 
(including defibrillator and medical grade oxygen, and intra-
muscular adrenaline (1:1000)66 for administration in case of 
anaphylaxis to sand fly bite).
Non-identifiable video and photography were recorded 
after written participant consent to document sand fly biting 
behaviour and any demonstrable evidence of sand fly bites. 
The participant was observed for an additional 2 hours for 
signs of any reactions or medical issues following removal 
of the sand fly biting chamber. Evidence of any sand fly 
bites present on the skin was recorded by digital dermatos-
copy (MoleScope II – Mobile Dermatoscope attached to an 
Apple iPhone 7). Study investigators examined the sand flies 
for evidence of blood-feeding by presence of a red translu-
cent swollen abdomen on visual and microscopic inspection. 
Participants were given a diary card to record daily fea-
tures at the sand fly bite site and any systemic adverse events. 
In each vector intervention arm, there was a further 1:1 
allocation of the biting aperture size to either 6mm or 8mm.
Follow-up visits. Follow-up visits took place at day 3 (±1 day), 
10 (± 3 days) and 21 (±5 days) following the biting visit. 
Participants were assessed for local and systemic adverse events 
using a focused history, clinical examination, dermoscopy 
and photography. Repeat blood sampling for a routine panel, 
PBMCs and serum were taken at each follow-up visit. Urinary 
β-human chorionic gonadotropin was tested in women at 
the day 10 and 21 visits. Serum IgE was taken at the day 3 and 
21 visit. Serum for ELISA assay for sand fly salivary gland 
protein antibodies was taken at the day 21 visit.
Focus groups. Focus group discussions at the end of the 
clinical study (after the last participant’s final follow-up 
visit) assessed the participants’ experiences in-depth includ-
ing acceptability, to inform the design of the subsequent CHIM 
study. Two focus group sessions took place with five partici-
pants from the sand fly biting study in each group (total n=10). 
The participant numbers were compatible with accepted 
methodology for focus groups67,68. The focus groups were 
recorded using digital audio with consent and each session 
lasted approximately 3 hours. The proceedings took place in 
accordance with a pre-prepared schedule, with specific ques-
tions agreed in advance with all investigators, to ensure 
appropriate coverage of key topics (Extended Data 250).Both 
sessions were chaired by GJ who acted as the independent 
facilitator and field notes were taken. The dialogue was fully 
transcribed verbatim and analysed using thematic analysis69, 
assisted by NVivo Pro software (version 12 QSR International 
Pty Ltd). Transcripts were not returned to participants. Data 
collection used a mixture of prescribed questions from the 
focus group schedule as well as open-ended discussion in order 
to achieve data saturation. Alternative open source software 
for qualitative analysis are available such as ATLAS.ti70.
Thematic analysis is a flexible approach for engaging with, 
identifying and analysing the meanings inherent within quali-
tative data. The goal of the analysis was to summarise and 
interpret the participants’ experiences. Therefore, an inductive 
thematic approach, utilising Braun and Clarke’s six key stages 
was undertaken69 to identify and prioritise their key con-
cerns and generate relevant themes71. The data was transcribed 
by a colleague external to the research team. Several mem-
bers of the team independently listened to the audio-recordings 
and read the two focus group transcripts (VP, GJ, NM). 
To establish the trustworthiness of the analysis, coding, at a 
semantic level, was undertaken to label items of interest in 
the data (NM)68. A second member of the team independently 
checked a proportion of coding against the transcripts (GJ). 
Together, and in an iterative process, NM and GJ actively 
searched and reviewed where codes clustered together to 
generate the key themes within each and across both focus 
groups.
Discussion of, and agreement upon, common patterns and 
broader themes from the participants’ experiences was reached 
by consensus. Any discrepant views and areas of diversity were 
considered and discussed with the wider study team. Clinical 
investigators were present to discuss the results of the study 
and to discuss future CHIM studies but were not present during 
discussion on attitudes to participation in the study.
Data analysis
Data tables are reported as mean (SD) or n (%). Groups were 
compared using independent t-test (continuous data), Mann 
Whitney (ordinal data) or chi-square tests (categorical data). 
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A p-value of <0.05 was considered to indicate statistical 
significance. All analyses were performed on IBM SPSS 
Statistics for Windows (Version 26.0. Armonk, NY; IBM Corp). 
Summaries of adverse events reported in the study are 
presented as summed data for all participants per adverse 
event or summed VAS score for each participant across all 
adverse events. Data are presented as median and range. 
Graphs were generated in GraphPad Prism v9.0.1. Alternate 
statistical packages could be used.
Results
Participant characteristics
Recruitment and screening took place from October to Novem-
ber 2019 and the follow-up period lasted until January 2020 
(Figure 1 and Figure 2; Extended Data 3). 55 participants 
were pre-screened and assessed for eligibility, of which 24 
attended for screening. In total, 12 participants were deemed 
eligible for entry into the study and were allocated to the 
P. papatasi arm (n = 6) or the P. duboscqi (n = 6) arm based 
on availability of sand fly species and date of recruitment. 
100% (12/12) of participants completed study visits to day 21 
post-sand fly biting and none were lost to follow-up. 10/12 
attended for the focus group exercise. Two participants were 
unable to attend the focus groups due to unforeseen per-
sonal circumstances unrelated to the study. The majority of 
exclusions following screening were due to raised serum IgE 
levels. Participant demographics and clinical characteristics 
at baseline are provided (Table 1; Extended Data 4 and 550). 
Gender representation was similar in each arm, with five 
female participants and one male participant recruited to each 
arm. Mean age in the P. papatasi arm was 40.8 years±12.8 
years, compared to the 39.5±11.9 years in the P. duboscqi arm. 
Participants had no unusual skin conditions; one had a tattoo 
and one a previous scar from an insect bite.
Primary outcome measures
Participants were exposed to sand flies in a bespoke chamber 
for 30 minutes (Figure 3; Extended Data 650). 100% (12/12) of 
participants received at least one successful sand fly bite. There 
was no apparent difference between sand fly species in terms 
of mean number of sand fly bites (7.00±2.76 vs 6.33±5.39 
for P. papatasi and P. duboscqi, respectively). Comparison of 
sand fly biting rate, defined as number of bites per 5 sand flies 
in 30 minutes also showed no significant difference (3.33±0.81 
vs 3.00±1.26 bites for P. papatasi and P. duboscqi, respec-
tively) although the study was not powered to detect a significant 
difference (Table 2). Successful biting was confirmed by the 
demonstration of red translucent swollen sand fly abdo-
mens on dissection subsequent to removal of the chamber. In 
all cases at least one sand fly demonstrated these characteris-
tics for each participant. There was no significant difference in 
the number of engorged sand flies post-biting between species 
(3.33±0.82 vs 3.00±1.27 for P. papatasi and P. duboscqi, 
respectively) (Table 3). Bites remained visible at the final visit 
at day 21, although they had reduced in number (3.17±1.60 
vs 3.50±3.73 for P. papatasi and P. duboscqi, respectively). 
Hence, the protocol was deemed to be 100% effective as each 
participant exposed to 5 sand flies received at least one bite, 
with at least one sand fly demonstrating evidence of feeding in 
each case.
Safety of sand fly bite
Solicited, or expected adverse events included bite site-related 
itch, pain, erythema, swelling, blistering or bullae, and ulcera-
tion. These events were graded based using a modified version 
of grading systems by the National Institutes of Health (NIH)72 
(Extended Data 750). Four grade 2 adverse events were noted. 
One participant was noted to have a new cardiac murmur at 
screening, prior to sand fly exposure, and this was recorded 
as a grade 2 adverse event. A further participant had a new 
cough at day 21, which was clinically suspected to be an unre-
lated upper respiratory tract infection. Just two study-related 
grade 2 adverse events were noted, both were solicited: erythema 
at the bite site and persistent itch at the bite site. No grade 3 
or higher adverse events were reported. No suspected unex-
pected serious adverse reactions (SUSARs) were reported 
(Extended Data 7 and 850). IgE was not affected by expo-
sure to sand fly bite. Mean CRP (normal range <5mg/L) on 
day 3 post-biting (5.00±4.24 vs 1.67±1.15), day 10 post-biting 
(3.67±2.31 vs 7.67±10.69) and day 21 post-biting (5.00±1.73 
vs 2.00±1.73) was not influenced by species of sand fly 
(P. papatasi and P. duboscqi described respectively). Hence, 
bite by uninfected P. papatasi and P. duboscqi is shown to 
be safe for healthy volunteers.
Figure 1. Schedule of events. Figure illustrates schedule of events with day of visit given in relation to biting visit (Day 0). Window for visits 
is indicated in brackets.
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Secondary outcome measures: VAS
Participant experience was recorded in both a quantitative 
(visual analogue daily diary card) and a qualitative manner 
(post-sand fly focus group). A daily diary card was recorded 
by all participants from 90 minutes following biting, until the 
last scheduled visit. There was a 100% response rate. A vis-
ual analogue scale (VAS73) on a 10 point scale was used by 
participants to record their daily experience for each of the 
following: itch, pain/discomfort, erythema, swelling and 
blistering at the bite site (Figure 4 and Figure 5; Extended 
Data 950). Systemic effects such as headache, malaise, myalgia 
and fever were also recorded. The mean VAS scoring was 
between 0–1 for each measure until day 21. The most 
commonly reported effects were localised erythema, swelling 
and itch. Based on this diary card data, the sand fly biting was 
well-tolerated with minimal adverse effects. Two participants 
reported an intercurrent viral upper respiratory tract infec-
tion, which may account for the increased incidence of malaise, 
myalgia and headache close to the end of the recorded 
diary card data. The viral infection was self-limiting in both 
cases and had resolved by the final visits. There was some 
recrudescence of swelling as reported by some participants 
towards the end of their study involvement, although this was 
minimal (Figure 5).
Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
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Some participants attended after the day 21 visit and were 
allowed to record diary card data until this visit. The mean 
score for erythema and swelling for these days was between 
2–3, although there were only limited participant responses on 
these days, as most participants had completed their involve-
ment in the study at this point. Additionally, the window 
period for each particular visit (Figure 1) also resulted in some 
participants attending for their final visit at day 18 post-biting.
Focus groups
In total, 10 participants took part in two focus groups (FG1 
and FG2). Each focus group consisted of five participants 
(each had four female and one male participant). In FG1, the 
age range of the females was 26 –51 years; in FG2, the age 
range was 21–59 years. The male participants were aged 38 
and 40 years old, respectively.
Overall, four overarching themes were identified: i) recruitment 
and quality of the participant-facing information, ii) screening 
process, iii) experience of being bitten, and iv) overall study 
experience. These themes are also described with the sub-
themes and exemplar quotes (Extended Data 1050). The similarity 
in themes across the two focus groups is demonstrated 
within a coded comparison diagram (Extended Data 1150). In 
particular, positive themes concerning the biting aspect, and the 
lack of significant post-bite reaction was shared by both focus 
groups. Full transcripts of the focus groups are provided 
(Extended Data 12 & 1350).
Recruitment and quality of the patient-facing 
information
The participants had become aware of the study via a number of 
recruitment methods including local and national advertisements 






n % n %
Gender
Female 5 83% 5 83%
Male 1 17% 1 17%
Eczema
No 4 67% 5 83%
Yes 2 33% 1 17%
Asthma
No 6 100% 4 67%
Yes 0 0% 2 33%
Urticaria No 6 100% 6 100%
Psoriasis No 6 100% 6 100%
Self-reported propensity to scarring No 6 100% 6 100%
Allergy to any medications (including over-
the-counter items)
No 4 67% 4 67%
Yes 2 33% 2 33%
Allergy to non-medications (including hay 
fever)
No 4 67% 4 67%
Yes 2 33% 2 33%
History of anaphylaxis No 6 100% 6 100%
Smoking history
Current 0 0% 1 17%
Never 5 83% 3 50%
Former 1 16.70% 2 33%
Travel outside the UK in the last 12 months
No 1 16.70% 2 33%
Yes 5 83.30% 4 67%
Travel outside Europe in the last 12 months
No 6 100.00% 4 67%
Yes 0 0.00% 2 33%
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Figure 3. Sand fly biting chamber and procedures. Photographs to illustrate key steps in the sand fly biting procedure. (A & B) Using 
fine tweezers, 5 sand flies are placed inside the biting chamber on ice. The sand fly biting chamber is approximately 5cm in diameter. (C) A 
gauze covering is placed over the bottom of the biting chamber with sand flies positioned inside. (D) Filter paper is used to form an aperture 
of between 6-8mm to limit the area of sand fly biting. (E & F) An adjustable Velcro strap is used to customise the fit for each participant, 
and biting chamber placed 3–4cm distal to the antecubital fossa. (G) Sand flies within the biting chamber; biting aperture with gauze visible 
(arrow). (H) Participant skin demonstrating pressure mark from biting chamber and small visible bite marks (circled). (I) Microscope image 
of sand fly, following biting on participants, with red swollen abdomen demonstrating blood meal has been taken and (J) sand fly following 
biting on participants with absence of red swollen abdomen suggesting blood meal has not been taken.
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Total white cell count (x 109/L) 6.78 1.61 6.55 2.06
Eosinophils (x 109/L) 0.13 0.08 0.10 0.09
C-reactive protein (mg/L) 2.67 2.08 1.67 1.15
IgE (KU/L) 24.53 13.88 38.87 28.13
Biting Day 
(Day 0)
Flies fed 3.33 0.82 3.00 1.26
Bites visible (30 minutes) 7.00 2.76 6.33 5.39
Bites visible (90 minutes) 6.17 2.40 5.00 2.97
Day 3 
post-biting
Bites visible 2.67 0.82 3.00 2.97
Size of biggest lesion (mm) 3.67 2.88 1.00 0.89
Total white cell count (x 109/L) 7.25 2.45 6.38 1.61
Eosinophils (x 109/L) 0.12 0.08 0.13 0.10
C-reactive protein (mg/L) 5.00 4.24 1.67 1.15
IgE (KU/L) 22.70 13.44 32.80 23.39
Day 10 
post-biting
Bites visible 2.67 1.37 2.83 3.37
Size of biggest lesion (mm) 3.50 3.56 3.00 4.69
Participant-reported pain (0-10 VAS) 0.00 0.00 0.00 0.00
Participant reported itch (0-10 VAS) 0.00 0.00 1.00 2.45
Erythema 1.00 0.63 0.83 0.98
Swelling 0.17 0.41 0.33 0.52
Blistering 0.17 0.41 0.17 0.41
Total white cell count (x 109/L) 7.88 1.43 5.98 1.23
Eosinophils (x 109/L) 0.15 0.10 0.17 0.12
C-reactive protein (mg/L) 3.67 2.31 7.67 10.69
Table 2. Sand fly biting comparison; Number of bites and biting rate (bites per 5 sand flies).
Type p-value
Phlebotomus duboscqi Phlebotomus papatasi
Mean SD n Mean SD n
30 mins -Reviewer 1: Number of bites 6 5 6 7 3 6 0.485
30 mins -Reviewer 1: Biting rate 1.3 1.1 6 1.4 0.6 6 0.485
30 mins -Reviewer 2: Number of bites 6 5 6 7 2 6 0.485
30 mins -Reviewer 2: Biting rate 1.3 1.1 6 1.4 0.5 6 0.485
90 mins -Reviewer 1: Number of bites 5 3 6 6 2 6 0.589
90 mins -Reviewer 1: Biting rate 1 0.6 6 1.2 0.5 6 0.589
90 mins -Reviewer 2: Number of bites 5 3 6 6 2 6 0.589
90 mins -Reviewer 2: Biting rate 1 0.6 6 1.2 0.5 6 0.589
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in posters (Extended Data 350), newsletters and mailing 
lists. Whilst the study website was perceived as clear and 
informative, it was not widely accessed by the participants prior 
to their involvement. The main reason cited for not using the 
website was because the investigators had provided all the 
information the participants required during initial contact, 
although it was suggested that the website should play a 
bigger role in future studies. Participants suggested verbal 
methods including talks and presentations might attract a wider 
demographic and help overcome information fatigue. Word-
of-mouth was also reported to have played an important role 
in recruitment. With respect to clarity of message some par-
ticipants commented on the importance of stating there would 
be financial compensation for taking part within the text of the 
advertisement although opposed specifying the exact amount. 
It was also commented that the use of social media would 
be beneficial in future advertising campaigns. The inclusion 
of a participant wearing a sand fly biting chamber on the poster 
was welcomed, although it was felt that there should be an 
effort to make the overall aesthetic more visually appealing in 
future.
“what appealed to me about the poster was that you actu-
ally showed the biting chamber because I think that was 
really useful because otherwise, I would have thought that 
I’d have perhaps been in a room being bitten by flies” (P10, 
FG1)
Participants stated that although the written material clearly 
specified the methods and details of the project, there should 
be greater focus on the humanitarian nature of the project and 
perceived end-goals. The quality of the participant-facing writ-
ten information was well received although some felt that 
more information about the medical examination was needed.
Screening process
The participants found the screening process beneficial in 
developing understanding of the project, exposure to scien-
tific researchers and for generalised health screening. Indeed, 
some of the participants volunteered that the process had 
uncovered a number of underlying health conditions for which 
they were now able to seek medical attention. It was felt 
that the screening process and testing had helped the partici-
pants to build a relationship with the team, and the continuity 
of care of the clinical team strengthened these positive 
relationships. Some participants described displeasure at the 
routine blood testing in general, including some pain and techni-
cal difficulties obtaining venous access. There was also some 
anxiety associated with waiting for pregnancy test results. 
Participants did however express gratitude for the testing in 
general. For some, the screening turned out to be more exten-
sive than they had initially expected, although they were 
pleased overall to have undergone a thorough examination.
“I thought it was quite nice. I know I’m healthy. I just didn’t 
realise that was going to be as extensive as it was.” (P6, FG1)
Experience of being bitten
The participants’ experiences of being bitten by sand flies was 
overwhelmingly positive. The sand flies were smaller than 
had been anticipated and the biting chamber was deemed to 
be relatively innocuous.
P14: “They were quite small yeah. I was expecting a bit 
bigger. (FG2)
P15: Because you couldn’t really see them.” (FG2)
Overall, the participants felt that taking part in the study had 













Bites visible 3.17 1.60 3.50 3.73
Size of biggest lesion (mm) 2.50 1.38 2.33 2.42
Erythema 1.17 0.75 1.00 0.89
Swelling 0.33 0.52 0.33 0.52
Blistering 0.00 0.00 0.00 0.00
Participant-reported pain (0-10 VAS) 0.00 0.00 0.00 0.00
Participant reported itch (0-10 VAS) 0.00 0.00 0.17 0.41
Total white cell count (x 109/L) 7.47 2.37 6.48 0.69
Eosinophils (x 109/L) 0.10 0.09 0.17 0.14
C-reactive protein (mg/L) 5.00 1.73 2.00 1.73
IgE (KU/L) 22.77 12.99 33.13 22.69
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Figure 4. Summed adverse events reported by type during FLYBITE. Adverse events were recorded by each participant at each visit 
on a visual analogue scale of 0-10 (see Methods). Pooled data for all 12 participants are presented separately for each adverse event (as 
indicated in panels) at each time point. Data are shown as median (circles) and range (vertical bar).
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Figure 5. Summed adverse events reported by individual participants during FLYBITE. Ten adverse events were recorded by each 
participant at each visit on a visual analogue scale of 0–10 (see Methods). Data are presented as the sum of all scores (out of 100) for each 
participant (as indicated in panels) at each time point.
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sand fly biting and events taking place as in line with prior 
explanation. The local cutaneous effects of the sand fly bite 
were minimal and the skin reaction generally had been less 
than had been expected. Overall, the bite was not painful but 
some participants experienced some minor blistering shortly 
after.
P7: “It [the bite] was unremarkable to the point where I 
forgot I was taking part in a medical study.” (FG1)
One participant had skin itchiness and whilst they needed 
to take over-the-counter antihistamines no other medication 
was required by any of the other participants. Another felt 
“glad” they had a small reaction as it demonstrated something 
was “happening”, and others described their curiosity and even 
‘excitement’ when the flies started to bite and witnessing 
them engorge.
P12: “[The bite itself] was really minor, much less, I mean 
just a tiny red mark and I was expecting you know a kind of 
a horrible itchy lump so it was much less than I expected.” 
(FG1)
P15: “[The bite] was just itchy so the more I itched it and 
then it got the skin slightly torn and then just looked like an 
insect bite, just a scratched insect bite that I would itch which 
made it worse.” (FG2)
However, there was some pre-bite anxiety. The participants 
described ‘worrying’ that biting might hurt, and ‘feeling 
slightly anxious’. But whilst the process was uneventful for 
most, it took longer than anticipated and the environment was 
felt to be clinical and a little uncomfortable during the wait-
ing period post-bite. The blood sampling procedure was per-
ceived to be more uncomfortable than the sand fly biting itself. 
Some participants struggled to remember to complete the post-
bite diary. For some, a paper-based diary was acceptable but 
others suggested that a phone app or text reminders on their 
phone might be useful. With the exception of one participant 
who struggled to remember the advice they were given, the 
remaining participants felt confident they had received all the 
information they needed to get in touch with the study team. 
They also described positively the follow-up support networks 
that the team had put in place.
Overall study experience
Overall, the participants described their experiences in the 
study positively and felt well-informed throughout. In particu-
lar, they described the team as professional and providing good 
communication.
P7: “it [involvement with the study and study team] was the 
most professional thing that’s happened to me in a long time.” 
(FG1)
The participants also enjoyed the social interaction with the 
study team and felt they had developed a good relationship 
with them, with one participant describing the team as ‘warm’. 
The participants also felt they were given enough opportunity 
to ask questions, had no safety concerns and felt appreciated, 
valued and well-cared for throughout the whole study.
Investigator: “Did you have any safety concerns at all when 
you were part of the project? The trial.
P(Several): No. (FG1)
Investigator: None at all?
P(Several): No.” (FG1)
At no point did any of the participants want to exit the 
study. However, for some, the time commitment was more 
than they had anticipated. Also, whilst they acknowledged the 
time commitment and would be willing to use other virtual or 
electronic follow-up methods, they still felt in-person contact 
was important and would wish this to continue. 
P16: “Well I work better with paper. I’m still a dinosaur 
when it comes to all the sort of technology and everything so 
for me it was fine to have to you know didn’t forget and took it 
with me and everything so yeah.” (FG2)
Finally, most of the participants thought the remuneration for 
taking part in the study was satisfactory and appropriate for 
the time commitment it necessitated. Despite this, the partici-
pants expressed differences of opinion regarding the impor-
tance of remuneration, with some stating that this was important 
versus others stating that it was not relevant. Most of the par-
ticipants expressed that they would have taken part in the 
current study for less and that the money was a bonus and 
secondary to their interest in the study. Although for one 
participant the financial incentive was the key motivator in 
their decision to take part (albeit they donated the money to 
charity).
P3: “getting some compensation makes you feel like your 
time is valuable, you know I have very little free time and to 
do it for nothing and take a lot of time off I would be reluctant 
to do that […] I don’t think everyone should have to do it for 
free, if you’d like to it’s not a bad thing to get a bit of money 
as part of it.” (FG1)
Other reasons given were a genuine altruistic interest in the 
condition/research, a belief that the study was meaningful and 
worthwhile, and a desire to help others in the advancement of 
science and world health. They felt these aspects of the 
study should be incorporated into any future recruitment and 
participant-facing materials in the future CHIM.
P16: “it’s my chance to sort of contribute to some sort of 
research which in the long run is going to hopefully benefit quite 
a few people.” (FG2)
Discussion
Deliberate human transmission of Leishmania has been used 
for centuries as part of cultural vaccination practice, typically 
using a sharp object to introduce the parasite33. Contemporary 
studies, after discovery of improved parasite culture techniques, 
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have also demonstrated infection by introduction of Leishma-
nia parasite to human subjects for both cutaneous and visceral 
forms32,74–76. Once the phlebotomine sand fly vector was impli-
cated in transmission, it was demonstrated to be the natural 
vector through indirect but deliberate human infection77.
Sand fly biting studies have a long history, although the major-
ity of studies have involved animal models. However, human 
exposure to non-infected sand fly bite has been studied 
both in order to attempt transmission to sand flies from a cuta-
neous lesion (xenodiagnosis)78, as well as demonstration of 
the sand fly bite reaction47,79. Several studies have since dem-
onstrated transmission of Leishmania to human subjects using 
phlebotomine sand flies80–82. A single individual was exposed to 
the bite of L. arabica-infected P. papatasi as part of a study 
on cross-protection, though no lesion developed83. We have 
described elsewhere a new Leishmania major strain suitable 
for use in a CHIM, with production of a clinical bank at Good 
Manufacturing Practices (GMP) and validation of its abil-
ity to infect P. papatasi and P. duboscqi sand flies and be 
transmitted to rodents through sand fly bite84.
The natural sand fly vectors of Leishmania major, P. papatasi 
and P. duboscqi, have a similar mode of feeding, and to-date 
there have been no major studies comparing biting rates on 
human subjects. This study serves to evaluate the biting rates and 
reproducibility between these sand fly species in order to deter-
mine effectiveness of the study protocol (Extended Data 150), 
whilst examining the safety aspects of sand fly biting on 
humans. There are no reported cases of serious adverse events 
such as anaphylaxis from exposure to these major sand fly 
species, although severe reactions including anaphylaxis 
have been reported rarely in some biting and hematophagous 
insects79,85,86.
It is increasingly recognised that public involvement in 
research is critical in ensuring high quality outcomes and robust 
practices and accountability87,88. As such, prior to undertaking 
this study we carried out a public involvement (PI) exer-
cise to inform the design and practical considerations in 
this research area49. The outcomes from this exercise sug-
gested that such a study was acceptable to participants 
and reinforced the need for clear and thorough written mate-
rials in order for true informed consent to be taken. We also 
describe here a further consultation exercise in the form of 
a focus group undertaken with the majority of study partici-
pants, to understand areas for improvement and barriers to 
involvement in a future CHIM study for cutaneous leishmaniasis.
All participants received at least one sand fly bite, and our 
results were in keeping with the known biting studies described. 
The number of bites sustained by an individual participant 
was not a factor that we were able to control given the techni-
cal and biological factors in animal studies. The number of 
bites observed by investigators after the removal of the biting 
chamber was, in the majority of cases, higher than the number 
of sand flies that fed, due to sand fly probing behaviour prior 
to settling for a sustained feed59. Of the many well described 
scoring systems for patient use in dermatological diseases, 
VAS is used frequently and has been shown to be valid and reli-
able for assessing dermatological disease in comparison with 
other scoring mechanisms73,89. Furthermore, there is a good 
correlation between VAS used in skin disease, and qual-
ity of life measures90. Our VAS data here demonstrates the 
first known description of a dermatological scoring system 
used in a sand fly biting study, although this has been described 
in other arthropod biting studies91 which further strengthens 
its use with sand fly bites. This study therefore demonstrates 
the safety and effectiveness of the protocol in preparation for 
its use in a Leishmania major CHIM. 
Given the perceptions that the public may have about delib-
erate human exposure within studies, public engagement is 
an important foundation for such projects. The chequered his-
tory of such studies add to this viewpoint19. Public involvement 
in CHIM studies has been well-described in other vector-borne 
CHIM studies, namely malaria92,93. With increasing descrip-
tions of new CHIM studies being mooted, so too the need 
for robust frameworks to ensure appropriate engagement is 
strengthened. This is especially true of CHIMs for development 
in LMICs94. The bioethical discussion surrounding such stud-
ies has included the utility and practicality of public involve-
ment and engagement within a rapidly changing landscape27,95. 
We initially conducted a PI study to inform the development 
of the FLYBITE protocol and here we report a comprehensive 
summary of focus group engagement following completion of 
our study. The key findings from our focus group demonstrate 
acceptability of sand fly biting on human participants, with 
routine blood tests, as a benchmark, seen to be less tolerable 
than the biting itself. Our results are in keeping with those 
reported by others in arthropod-based CHIM studies, who sug-
gest that the anticipation of harm from such studies fluctuates 
over time. In our focus group study and the underpinning 
PI study, it was noted that education was important to over-
coming barriers and negative public perception, in common 
with themes described elsewhere92.
Although this study was successful, there are some limita-
tions. First, it is known that sand fly behaviour is altered 
following infection with Leishmania parasites, although usu-
ally this is associated with increased bite rate96. Though previ-
ous studies on mice revealed that L. major-infected females 
of both species readily take a bloodmeal on mice84, and 
P. duboscqi infected with L. major can cause cutaneous leish-
maniasis in mice97 and non-human primates98, we cannot be cer-
tain that the biting characteristics on human subjects will be 
faithfully reproduced using infected sand flies in a CHIM 
study. The second issue relates to uniformity between partici-
pants, which may impact on outcomes from a future CHIM. 
For example, some participants were noted to have persist-
ent but improving sand fly bite reaction at the final 21-day 
follow-up visit, whilst most participants had completely 
healed skin at the site of biting. An extended follow-up 
period would have allowed for greater characterisation of this 
variation in response. As Leishmania major is associated 
with lesion development at around 4 weeks post-inoculation, 
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and based on our observations of skin appearance at 21 days 
post-bites, it may prove difficult to visually distinguish an 
early cutaneous leishmaniasis lesion from a persistent sand 
fly bite reaction32,99. The third issue related to the focus group 
study, which although was an efficient process and stimulated 
group interaction that uncovered themes that may not have 
come to light with individual interviews100, individual inter-
views have been shown to provide greater understanding of 
participant knowledge101.
In conclusion, the successful completion of this study comple-
ments further research aimed at developing a CHIM model 
for leishmaniasis. As reported elsewhere84, using a new fully 
characterised strain of Leishmania major, we have manufactured 
a clinical parasite bank under GMP conditions and confirmed 
that this isolate is fully transmissible to rodents via the bite of 
either P. papatasi and P. dubosqi. How well these preclinical 
and clinical studies translate into an effective CHIM will be 
addressed in a subsequent clinical study (LEISH_Challenge; 
ClinicalTrials.gov ID NCT04512742). If successful, this CHIM 
will provide a new tool to assess vaccine efficacy allowing sub-




Open Science Framework: A controlled human infection 
model for sand fly-transmitted cutaneous leishmaniasis. 
https://doi.org/10.17605/OSF.IO/H3UCA50.
This project contains the following underlying data:
•  Figure 4 Raw data (Summed adverse events reported 
by type during FLYBITE)
•  Figure 5 Raw data (Summed adverse events reported 
by individual participants during FLYBITE)
•  Raw data supporting Extended Data 4 (baseline 
screening blood tests)
•  Raw data supporting Extended Data 4 and 5 (baseline 
physical examination characteristics)
•  Raw data supporting Extended Data 9 (participant-
reported diary card data)
Extended data
Open Science Framework: A controlled human infection 
model for sand fly-transmitted cutaneous leishmaniasis. 
https://doi.org/10.17605/OSF.IO/H3UCA50.
This project contains the following extended data:
•  Extended Data 1 (Study protocol)
•  Extended Data 2 (Focus group schedule)
•  Extended Data 3 (Recruitment poster) 
•  Extended Data 4 (Baseline medical examination 
characteristics of participants)
•  Extended Data 5 (Skin examination findings at 
baseline)
•  Extended Data 6 (Sand fly biting video)
•  Extended Data 7 (Adverse event grading system for 
solicited study events)
•  Extended Data 8 (part 1; dermoscopy)
•  Extended Data 8 (part 2; dermoscopy)
•  Extended Data 9 (Data file supporting Figure 4: 
Summary of participant-reported diary card data; 
Visual analogue scoring 0–10)
•  Extended Data 10 (Table of themes, with exemplar 
quotations)
•  Extended Data 11 (Coded comparison diagrams of 
focus group FG1 and focus group FG2)
•  Extended Data 12 (Anonymised transcripts for focus 
group FG1)
•  Extended Data 13 (Anonymised transcripts for focus 
group FG2)
•  CONSORT 2010 Checklist
Reporting guidelines
Open Science Framework: CONSORT checklist for ‘A clini-
cal study to optimise a sand fly biting protocol for use in a 
controlled human infection model of cutaneous leishmaniasis 
(the FLYBITE study). https://doi.org/10.17605/OSF.IO/H3UCA50.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Consent
Written informed consent for publication of the participants 
details and their images was obtained from all participants.
Acknowledgements
The authors wish to thank the clinical research nurses (Nicola 
Marshall and Joanne Ingham) and clinical trials assistant 
(David Thompson), as well as the Research and Develop-
ment and laboratory support team at York Teaching Hospitals 
NHS Foundation Trust for their support and valued input. The 
authors would also wish to thank Amber Rithalia at Leeds 
Beckett University for undertaking the transcriptions of the 
focus group recordings. Lastly, the authors thank all the study 
participants for their dedication to this study.
Page 16 of 23
Wellcome Open Research 2021, 6:168 Last updated: 11 OCT 2021
References
1.  Control of Neglected Tropical Diseases.  
Reference Source
2.  GBD 2017 Causes of Death Collaborators: Global, regional, and national 
age-sex-specific mortality for 282 causes of death in 195 countries and 
territories, 1980-2017: a systematic analysis for the Global Burden of 
Disease Study 2017. Lancet. 2018; 392(10159): 1736–1788.  
PubMed Abstract | Publisher Full Text | Free Full Text 
3.  WHO: Weekly Epidemiological Record, 19 June 2020. WHO, 2020; 95(25): 
265–280.  
Reference Source
4.  Alvar J, Vélez ID, Bern C, et al.: Leishmaniasis Worldwide and Global 
Estimates of Its Incidence. PLoS One. 2012; 7(5): e35671.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5.  Leishmaniasis.  
Reference Source
6.  GBD 2019 Diseases and Injuries Collaborators: Global burden of 369 diseases 
and injuries in 204 countries and territories, 1990– 2019: a systematic 
analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 
396(10258): 1204–1222.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7.  Bennis I, De Brouwere V, Belrhiti Z, et al.: Psychosocial burden of localised 
cutaneous Leishmaniasis: a scoping review. BMC Public Health. 2018; 18(1): 
358.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8.  Kamhawi S: Phlebotomine sand flies and Leishmania parasites: friends or 
foes? Trends Parasitol. 2006; 22(9): 439–45.  
PubMed Abstract | Publisher Full Text 
9.  Dostálová A, Volf P: Leishmania development in sand flies: Parasite-vector 
interactions overview. Parasit Vectors. 2012; 5: 276.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10.  Chakravarty J, Sundar S: Current and emerging medications for the 
treatment of leishmaniasis. Expert Opin Pharmacother. 2019; 20(10):  
1251–1265.  
PubMed Abstract | Publisher Full Text 
11.  Travi BL, Cordeiro-da-Silva A, Dantas-Torres F, et al.: Canine visceral 
leishmaniasis: Diagnosis and management of the reservoir living among 
us. PLoS Negl Trop Dis. 2018; 12(1): e0006082.  
PubMed Abstract | Publisher Full Text | Free Full Text 
12.  Mondal D, Bern C, Ghosh D, et al.: Quantifying the infectiousness of post-
kala-azar dermal leishmaniasis toward sand flies. Clin Infect Dis. 2019; 69(2): 
251–258.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13.  Wilson AL, Courtenay O, Kelly-Hope LA, et al.: The importance of vector 
control for the control and elimination of vector-borne diseases. PLoS Negl 
Trop Dis. 2020; 14(1): e0007831.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14.  Le Rutte EA, Coffeng LE, Malvolti S, et al.: The potential impact of human 
visceral leishmaniasis vaccines on population incidence. PLoS Negl Trop Dis. 
2020; 14(7): e0008468.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15.  Gillespie PM, Beaumier CM, Strych U, et al.: Status of vaccine research and 
development of vaccines for leishmaniasis. Vaccine. 2016; 34(26): 2992–2995. 
PubMed Abstract | Publisher Full Text 
16.  Alvar J, Croft SL, Kaye P, et al.: Case study for a vaccine against leishmaniasis. 
Vaccine. 2013; 31 Suppl 2: B244–B249.  
PubMed Abstract | Publisher Full Text 
17.  Palatnik-de-Sousa CB, Nico D: The Delay in the Licensing of Protozoal 
Vaccines: A Comparative History. Front Immunol. 2020; 11: 204.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18.  Payne RO, Griffin PM, McCarthy JS, et al.: Plasmodium vivax Controlled Human 
Malaria Infection - Progress and Prospects. Trends Parasitol. 2017; 33(2): 
141–150.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19.  Darton TC, Blohmke CJ, Moorthy VS, et al.: Design, recruitment, and 
microbiological considerations in human challenge studies. Lancet Infect 
Dis. 2015; 15(7): 840–51.  
PubMed Abstract | Publisher Full Text 
20.  Roestenberg M, Hoogerwerf MA, Ferreira DM, et al.: Experimental infection of 
human volunteers. Lancet Infect Dis. 2018; 18(10): e312–e322.  
PubMed Abstract | Publisher Full Text 
21.  Gould VMW, Francis JN, Anderson KJ, et al.: Nasal IgA Provides Protection 
against Human Influenza Challenge in Volunteers with Low Serum 
Influenza Antibody Titre. Front Microbiol. 2017; 8: 900.  
PubMed Abstract | Publisher Full Text | Free Full Text 
22.  Newman KL, Marsh Z, Kirby AE, et al.: Immunocompetent adults from human 
norovirus challenge studies do not exhibit norovirus viremia. J Virol. 2015; 
89(13): 6968–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23.  Kirkpatrick BD, Whitehead SS, Pierce KK, et al.: The live attenuated dengue 
vaccine TV003 elicits complete protection against dengue in a human 
challenge model. Sci Transl Med. 2016; 8(330): 330ra36.  
PubMed Abstract | Publisher Full Text 
24.  Ferreira DM, Neill DR, Bangert M, et al.: Controlled human infection and 
rechallenge with Streptococcus pneumoniae reveals the protective efficacy 
of carriage in healthy adults. Am J Respir Crit Care Med. 2013; 187(8): 855–64. 
PubMed Abstract | Publisher Full Text | Free Full Text 
25.  Langenberg MCC, Hoogerwerf MA, Koopman JPR, et al.: A controlled human 
Schistosoma mansoni infection model to advance novel drugs, vaccines and 
diagnostics. Nat Med. 2020; 26(3): 326–332.  
PubMed Abstract | Publisher Full Text 
26.  Eyal N, Lipsitch M, Smith PG: Human Challenge Studies to Accelerate 
Coronavirus Vaccine Licensure. J Infect Dis. 2020; 221(11): 1752–1756. 
PubMed Abstract | Publisher Full Text | Free Full Text 
27.  Shah SK, Miller FG, Darton TC, et al.: Ethics of controlled human infection to 
address COVID-19. Science. 2020; 368(6493): 832–834.  
PubMed Abstract | Publisher Full Text 
28.  Peters NC, Bertholet S, Lawyer PG, et al.: Evaluation of Recombinant 
Leishmania Polyprotein Plus Glucopyranosyl Lipid A Stable Emulsion 
Vaccines against Sand Fly-Transmitted Leishmania major in C57BL/6 Mice.  
J Immunol. 2012; 189(10): 4832–41.  
PubMed Abstract | Publisher Full Text | Free Full Text 
29.  Dey R, Joshi AB, Oliveira F, et al.: Gut Microbes Egested during Bites of 
Infected Sand Flies Augment Severity of Leishmaniasis via Inflammasome-
Derived IL-1β. Cell Host Microbe. 2018; 23(1): 134–143.e6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
30.  DeSouza-Vieira T, Iniguez E, Serafim TD, et al.: Heme Oxygenase-1 Induction 
by Blood-Feeding Arthropods Controls Skin Inflammation and Promotes 
Disease Tolerance. Cell Rep. 2020; 33(4): 108317.  
PubMed Abstract | Publisher Full Text 
31.  Nagill R, Kaur S: Vaccine candidates for leishmaniasis: A review. Int 
Immunopharmacol. 2011; 11(10): 1464–88.  
PubMed Abstract | Publisher Full Text 
32.  Khamesipour A, Dowlati Y, Asilian A, et al.: Leishmanization: Use of an old 
method for evaluation of candidate vaccines against leishmaniasis. 
Vaccine. 2005; 23(28): 3642–3648.  
PubMed Abstract | Publisher Full Text 
33.  Mohebali M, Nadim A, Khamesipour A: An overview of leishmanization 
experience: A successful control measure and a tool to evaluate candidate 
vaccines. Acta Trop. 2019; 200: 105173.  
PubMed Abstract | Publisher Full Text 
34.  Osman M, Mistry A, Keding A, et al.: A third generation vaccine for human 
visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-
human trial of ChAd63-KH. PLoS Negl Trop Dis. 2017; 11(5): e0005527.  
PubMed Abstract | Publisher Full Text | Free Full Text 
35.  Duthie MS, Pereira L, Favila M, et al.: A defined subunit vaccine that protects 
against vector-borne visceral leishmaniasis. NPJ Vaccines. 2017; 2: 23. 
PubMed Abstract | Publisher Full Text | Free Full Text 
36.  Laurent I, et al.: Leishmania vaccine using sand fly salivary immunogen. 
2013; 2. 
37.  IRCT: Evaluations of double blind randomized controlled clinical trial, 
single dose of the gentamicin-attenuated line of Leishmania major H-line 
vaccine against cutaneous leishmaniasis in comparison with phosphate 
buffer solution control group in west of Iran.  
Reference Source
38.  Zabala-Peñafiel A, Todd D, Daneshvar H, et al.: The potential of live 
attenuated vaccines against Cutaneous Leishmaniasis. Exp Parasitol. 2020; 
210: 107849.  
PubMed Abstract | Publisher Full Text 
39.  Zhang WW, Karmakar S, Gannavaram S, et al.: A second generation 
leishmanization vaccine with a markerless attenuated Leishmania major 
strain using CRISPR gene editing. Nat Commun. 2020; 11(1): 3461.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40.  Cecílio P, Oristian J, Meneses C, et al.: Engineering a vector-based pan-
Leishmania vaccine for humans: proof of principle. Sci Rep. 2020; 10(1): 
18653.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41.  Lestinova T, Rohousova I, Sima M, et al.: Insights into the sand fly saliva: 
Blood-feeding and immune interactions between sand flies, hosts, and 
Leishmania. PLoS Negl Trop Dis. 2017; 11(7): e0005600.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42.  Atayde VD, Aslan H, Townsend S, et al.: Exosome Secretion by the Parasitic 
Protozoan Leishmania within the Sand Fly Midgut. Cell Rep. 2015; 13(5): 
957–67.  
PubMed Abstract | Publisher Full Text 
43.  Atayde VD, Hassani K, da Silva Lira Filho A, et al.: Leishmania exosomes 
and other virulence factors: Impact on innate immune response and 
macrophage functions. Cell Immunol. 2016; 309: 7–18.  
PubMed Abstract | Publisher Full Text 
Page 17 of 23
Wellcome Open Research 2021, 6:168 Last updated: 11 OCT 2021
44.  Kaye PM, Cruz I, Picado A, et al.: Leishmaniasis immunopathology—impact 
on design and use of vaccines, diagnostics and drugs. Semin Immunopathol. 
2020; 42(3): 247–264.  
PubMed Abstract | Publisher Full Text 
45.  Vinhas V, Andrade BB, Paes F, et al.: Human anti-saliva immune response 
following experimental exposure to the visceral leishmaniasis vector, 
Lutzomyia longipalpis. Eur J Immunol. 2007; 37(11): 3111–21.  
PubMed Abstract | Publisher Full Text 
46.  Luz NF, DeSouza-Vieira T, De Castro W, et al.: Lutzomyia longipalpissaliva 
induces heme oxygenase-1 expression at bite sites. Front Immunol. 2018; 9: 
2779.  
PubMed Abstract | Publisher Full Text | Free Full Text 
47.  Oliveira F, Traoré B, Gomes R, et al.: Delayed-type hypersensitivity to sand 
fly saliva in humans from a leishmaniasis-endemic area of mali is TH1-
mediated and persists to midlife. J Invest Dermatol. 2013; 133(2): 452–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
48.  Immune Responses After Human Subject Challenge With Sand Fly Bites. 
Full Text View - ClinicalTrials.gov.  
Reference Source 
49.  Parkash V, Jones G, Martin N, et al.: Assessing public perception of a sand fly 
biting study on the pathway to a controlled human infection model for 
cutaneous leishmaniasis. Res Involv Engagem. 2021; 7(1): 33.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50.  Kaye P: A controlled human infection model for sand fly-transmitted 
cutaneous leishmaniasis. 2021.  
http://www.doi.org/10.17605/OSF.IO/H3UCA
51.  A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol. Full Text 
View - ClinicalTrials.gov.  
Reference Source
52.  Herrington DA, Clyde DF, Murphy JR, et al.: A model for Plasmodium falciparum 
sporozoite challenge and very early therapy of parasitaemia for efficacy 
studies of sporozoite vaccines. Trop Geogr Med. 1988; 40(2): 124–127.  
PubMed Abstract 
53.  Cheng Q, Lawrence G, Reed C, et al.: Measurement of Plasmodium falciparum 
growth rates in vivo: A test of malaria vaccines. Am J Trop Med Hyg. 1997; 
57(4): 495–500.  
PubMed Abstract | Publisher Full Text 
54.  Home - Leish Challenge.  
Reference Source
55.  Sherrill DL, Halonen M, Burrows B: Relationships between total serum IgE, 
atopy, and smoking: A twenty-year follow-up analysis. J Allergy Clin Immunol. 
1994; 94(6 Pt 1): 954–62.  
PubMed Abstract | Publisher Full Text 
56.  Ben-Shoshan M, Clarke AE: Anaphylaxis: Past, present and future. Allergy. 
2011; 66(1): 1–14.  
PubMed Abstract | Publisher Full Text 
57.  Volf P, Volfova V: Establishment and maintenance of sand fly colonies.  
J Vector Ecol. 2011; 36 Suppl 1: S1–S9.  
PubMed Abstract | Publisher Full Text 
58.  Lawyer P, Killick-Kendrick M, Rowland T, et al.: Laboratory colonization and 
mass rearing of phlebotomine sand flies (Diptera, Psychodidae). Parasite. 
2017; 24: 42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
59.  Killick-Kendrick R: The biology and control of Phlebotomine sand flies. Clin 
Dermatol. 1999; 17(3): 279–89.  
PubMed Abstract | Publisher Full Text 
60.  Benkova I, Volf P: Effect of temperature on metabolism of Phlebotomus 
papatasi (Diptera: Psychodidae). J Med Entomol. 2007; 44(1): 150–4.  
PubMed Abstract 
61.  Rohousova I, Ozensoy S, Ozbel Y, et al.: Detection of species-specific 
antibody response of humans and mice bitten by sand flies. Parasitology. 
2005; 130(Pt 5): 493–9.  
PubMed Abstract | Publisher Full Text 
62.  Clements MF, Gidwani K, Kumar R, et al.: Measurement of recent exposure 
to Phlebotomus argentipes, the vector of indian visceral leishmaniasis, by 
using human antibody responses to sand fly saliva. Am J Trop Med Hyg. 2010; 
82(5): 801–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
63.  Hamilton JG, Ramsoondar TM: Attraction of Lutzomyia longipalpis to human 
skin odours. Med Vet Entomol. 1994; 8(4): 375–80.  
PubMed Abstract | Publisher Full Text 
64.  Rebollar-Tellez EA, Hamilton JGC, Ward RD: Response of female Lutzomyia 
longipalpis to host odour kairomones from human skin. Physiol Entomol. 
1999; 24(3): 220–226.  
Publisher Full Text 
65.  Nevatte TM, Ward RD, Sedda L, et al.: After infection with Leishmania 
infantum, Golden Hamsters (Mesocricetus auratus) become more attractive 
to female sand flies (Lutzomyia longipalpis). Sci Rep. 2017; 7(1): 6104.  
PubMed Abstract | Publisher Full Text | Free Full Text 
66.  Simpson CR, Sheikh A: Adrenaline is first line treatment for the emergency 
treatment of anaphylaxis. Resuscitation. 2010; 81(6): 641–2.  
PubMed Abstract | Publisher Full Text 
67.  Caroline Tynan A, Drayton JL: CONDUCTING FOCUS GROUPS — A GUIDE FOR 
FIRST‐TIME USERS. Mark Intell Plan. 1988; 6(1): 5–9.  
Publisher Full Text 
68.  Noble H, Smith J: Issues of validity and reliability in qualitative research. 
Evid Based Nurs. 2015; 18(2): 34–35.  
PubMed Abstract | Publisher Full Text 
69.  Braun V, Clarke V: Using thematic analysis in psychology. Qual Res Psychol. 
2006; 3(2): 77–101.  
Publisher Full Text 
70.  Friese S: Qualitative Data Analysis with ATLAS.ti. SAGE Publications, 2019. 
Reference Source
71.  Elo S, Kääriäinen M, Kanste O, et al.: Qualitative Content Analysis: A Focus on 
Trustworthiness. SAGE Open. 2014; 4: 215824401452263.  
Publisher Full Text 
72.  U.S. Department of Health and Human Services, National Institutes of Health, 
National Institute of Allergy and Infectious Diseases, Division of AIDS: Division 
of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric 
Adverse Events. Corrected.  
Reference Source
73.  Reich A, Heisig M, Phan NQ, et al.: Visual analogue scale: Evaluation of the 
instrument for the assessment of pruritus. Acta Derm Venereol. 2012; 92(5): 
497–501.  
PubMed Abstract | Publisher Full Text 
74.  Senekji HA, Beattie CP: Artificial infection and immunization of man with 
cultures of leishmania tropica. Trans R Soc Trop Med Hyg. 1941; 34(6): 415–419. 
Publisher Full Text 
75.  Melby PC: Experimental leishmaniasis in humans: review. Rev Infect Dis. 
1991; 13(5): 1009–17.  
PubMed Abstract | Publisher Full Text 
76.  Adler S: Attempts to transmit visceral leishmaniasis to man: Remarks on 
the histopathology of leishmaniasis. Trans R Soc Trop Med Hyg. 1940; 33(4): 
419–426.  
Publisher Full Text 
77.  de la Tribonnière X: [b1 b2] (analytic). Edmond SERGENT (1876-1969) et 
l’Institut Pasteur d’Algérie (French). Edmond SERGENT Pasteur Inst Alger. (1AD). 
78.  Adler S, Theodor O: The transmission of leishmania tropica from artificially 
infected sandflies to man. Ann Trop Med Parasitol. 1927; 21(2): 89–110. 
Publisher Full Text 
79.  Theodor O: A study of the reaction to phlebotomus bites with some 
remarks on “Harara”. Trans R Soc Trop Med Hyg. 1935; 29(3): 273–284. 
Publisher Full Text 
80.  Adler S, Ber M: Transmission of Leishmania tropica by the Bite of 
Phlebotomus papatasii. Nature. 1941; 148: 227.  
Publisher Full Text 
81.  Swaminath CS, Shortt HE, Anderson LA: Transmission of Indian kala-azar to 
man by the bites of Phlebotomus argentipes, ann and brun. 1942. Indian J 
Med Res. 2006; 123(3): 473–7.  
PubMed Abstract 
82.  Lainson R, Strangways-Dixon J: Leishmania mexicana: The epidemiology of 
dermal leishmaniasis in British Honduras. Trans R Soc Trop Med Hyg. 1963; 
242–65.  
PubMed Abstract | Publisher Full Text 
83.  Peters W, Bryceson A, Evans DA, et al.: Leishmania infecting man and wild 
animals in Saudi Arabia. 8. The influence of prior infection with Leishmania 
arabica on challenge with L. major in man. Trans R Soc Trop Med Hyg. 1990; 
84(5): 681–9.  
PubMed Abstract | Publisher Full Text 
84.  Ashwin H, Sadlova J, Vojtkova B, et al.: Characterization of a new Leishmania 
major strain for use in a controlled human infection model. Nat Commun. 
2021; 12(1): 215.  
PubMed Abstract | Publisher Full Text | Free Full Text 
85.  Belkaid Y, Valenzuela JG, Kamhawi S, et al.: Delayed-type hypersensitivity to 
Phlebotomus papatasi sand fly bite: An adaptive response induced by the 
fly? Proc Natl Acad Sci U S A. 2000; 97(12): 6704–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
86.  Klotz JH, Klotz SA, Pinnas JL: Animal Bites and Stings with Anaphylactic 
Potential. J Emerg Med. 2009; 36(2): 148–56.  
PubMed Abstract | Publisher Full Text 
87.  Crocker JC, Ricci-Cabello I, Parker A, et al.: Impact of patient and public 
involvement on enrolment and retention in clinical trials: Systematic 
review and meta-analysis. BMJ. 2018; 363: k4738.  
PubMed Abstract | Publisher Full Text | Free Full Text 
88.  Bagley HJ, Short H, Harman NL, et al.: A patient and public involvement (PPI) 
toolkit for meaningful and flexible involvement in clinical trials – a work in 
progress. Res Involv Engagem. 2016; 2: 15.  
PubMed Abstract | Publisher Full Text | Free Full Text 
89.  Li L, Liu X, Herr K: Postoperative pain intensity assessment: A comparison of 
four scales in Chinese adults. Pain Med. 2007; 8(3): 223–34.  
PubMed Abstract | Publisher Full Text 
90.  Flytström I, Stenberg B, Svensson Å, et al.: Patients’ visual analogue scale: 
A useful method for assessing psoriasis severity. Acta Derm Venereol. 2012; 
92(4): 347–9.  
PubMed Abstract | Publisher Full Text 
91.  Reunala T, Brummer-Korvenkontio H, Petman L, et al.: Effect of ebastine on 
Page 18 of 23
Wellcome Open Research 2021, 6:168 Last updated: 11 OCT 2021
mosquito bites. Acta Derm Venereol. 1997; 77(4): 315–6.  
PubMed Abstract 
92.  Jao I, Marsh V, Chi PC, et al.: Deliberately infecting healthy volunteers with 
malaria parasites: Perceptions and experiences of participants and other 
stakeholders in a Kenyan-based malaria infection study. Bioethics. 2020; 
34(8): 819–832.  
PubMed Abstract | Publisher Full Text | Free Full Text 
93.  Njue M, Njuguna P, Kapulu MC, et al.: Ethical considerations in Controlled 
Human Malaria Infection studies in low resource settings: Experiences and 
perceptions of study participants in a malaria Challenge study in Kenya 
[version 1; referees: 2 approved]. Wellcome Open Res. 2018; 3: 39.  
PubMed Abstract | Publisher Full Text | Free Full Text 
94.  Kapumba BM, Jambo K, Rylance J, et al.: Stakeholder views on the 
acceptability of human infection studies in Malawi. BMC Med Ethics. 2020; 
21(1): 14.  
PubMed Abstract | Publisher Full Text | Free Full Text 
95.  Gbesemete D, Barker M, Lawrence WT, et al.: Exploring the acceptability of 
controlled human infection with SARSCoV2 - A public consultation. BMC 
Med. 2020; 18(1): 209.  
PubMed Abstract | Publisher Full Text | Free Full Text 
96.  Rogers ME, Bates PA: Leishmania manipulation of sand fly feeding behavior 
results in enhanced transmission. PLoS Pathog. 2007; 3(6): e91.  
PubMed Abstract | Publisher Full Text | Free Full Text 
97.  Teixeira C, Gomes R, Oliveira F, et al.: Characterization of the Early 
Inflammatory Infiltrate at the Feeding Site of Infected Sand Flies in Mice 
Protected from Vector-Transmitted Leishmania major by Exposure to 
Uninfected Bites. PLoS Negl Trop Dis. 2014; 8(4): e2781.  
PubMed Abstract | Publisher Full Text | Free Full Text 
98.  Oliveira F, Rowton E, Aslan H, et al.: A sand fly salivary protein vaccine shows 
efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman 
primates. Sci Transl Med. 2015; 7(290): 290ra90.  
PubMed Abstract | Publisher Full Text 
99.  El Hajj L, Thellier M, Carrière J, et al.: Localized cutaneous leishmaniasis 
imported into Paris: A review of 39 cases. Int J Dermatol. 2004; 43(2): 120–5. 
PubMed Abstract | Publisher Full Text 
100.  McLafferty I: Focus group interviews as a data collecting strategy. J Adv Nurs. 
2004; 48(2): 187–94.  
PubMed Abstract | Publisher Full Text 
101.  Morgan D: Focus groups. Annu Rev Sociol. 1996; 22: 129–152.  
Publisher Full Text 
Page 19 of 23
Wellcome Open Research 2021, 6:168 Last updated: 11 OCT 2021
Open Peer Review
Current Peer Review Status:   
Version 1
Reviewer Report 11 October 2021
https://doi.org/10.21956/wellcomeopenres.18609.r46214
© 2021 Hashiguchi Y. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Yoshihisa Hashiguchi  
Department of Parasitology, Kochi Medical School, Kochi University, Nankoku, Japan 
This article on a clinical study to optimize a sand fly biting protocol for use in a controlled human 
infection model (CHIM) of cutaneous leishmaniasis (CL) through the fly bite study is interesting 
and important for future steps aimed at vaccine development. The study employed Leishmania 
major, one of the less human pathogenic species in the genus and the natural vectors Phlebotomus 
papatasi and P. duboscqi, and human participants (volunteers). The results validate a protocol for 
achieving successful sand fly bites in humans that is safe, well-tolerated and acceptable for study 
participants. In vector-borne diseases such as leishmaniasis and malaria, an establishment of 
CHIM would be crucial and provide a novel method for early evaluation of prophylactic efficacy of 
candidate vaccines. 
  
Historically, as mentioned by the authors, deliberate human infection with live or attenuated 
Leishmania parasites had been practiced for centuries by people living in the Middle East and 
former Soviet Union regions, where CL is highly endemic. Build on the knowledge that cure from 
CL engendered protection against reinfection (“leishmanization”), scrapings from active lesions 
were used to cause skin lesions at a selected site of the body, thereby avoiding the stigmatization 
associated with CL scars (overviewed by Mohebali et al., 2019).  Such available information 
supports the idea or belief that the leishmaniases are vaccine preventable disease, including 
demonstrable immunity following infection and self-cure; “Leishmanization” in areas endemic for 
CL involved the inoculation of live virulent (cultured) parasites into cosmetically less conspicuous 
body areas, typically on the buttock. More defined experimental studies were conducted 
sporadically through the 20th century, evaluating vaccines for leishmaniasis. In recent years, 
different types of candidate vaccines against leishmaniasis are in development, including an 
adjuvanted recombinant polyprotein vaccine and RNA-based vaccines. Besides, the authors 
research group and others reported novel findings regarding the integral nature of sand fly 
transmission to Leishmania infectivity; namely, vaccines inducing protection in mice when infected 
via needle inoculation (“needle infection”) fail to protect against sand fly-transmitted infection (“fly 
bite infection”: influence of the saliva). 
  
The current CHIM tested provides a pathway and an important step for accelerating vaccine 
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development and to more fully understand disease pathogenesis and correlates of protection, 
including other vector-borne diseases such as malaria and trypanosomiasis, and etc.  
Furthermore, as mentioned by the authors, the successful completion of this study complements 
further research aimed at developing a CHIM model for leishmaniasis, using the authors’ fully 
characterized strain of L. major; the isolate is fully transmissible to rodents via the bite of both P. 
papatasi and P. dubosqi. Again, the current CHIM model tested will provide a new tool to assess 
vaccine efficacy allowing subsequent evidence-based decisions to be made on progression of 
candidate vaccines. 
  
The study is well designed and organized, and the manuscript is well written, followed a logical 
progression. Finally, it is noteworthy that sand flies tested in this study were provided different 
blood sources at the first and the second meal, the former, rabbit and the latter, human. So, it 
would be interesting to investigate how those blood-meal differences would influence the 
outcome of such a CHIM study.
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This article on developing a sand fly biting protocol for use in controlled human infection models 
(CHIM) of leishmaniasis is an important step towards the goal of testing and ultimately deploying 
vaccines against the leishmaniases, a complex group of diseases caused by many Leishmania 
species, but which have certain features in common. As noted by the authors the majority of the 
leishmaniases affect the skin, whilst some species can cause visceral disease, but even the latter 
originate as skin infections in which what happens at that site certainly influences whether the 
infection metastasises to visceral sites. Therefore, studies such as this that will enable use of 
natural transmission via the skin in CHIM are critical. I agree that there is good evidence that the 
leishmaniases are vaccine-preventable diseases, but would be cautious that they could be 
eliminated, given that the majority are zoonoses, and even those that are supposedly 
anthroponotic in transmission have zoonotic roots. Therefore, we will have to live with the threat 
of leishmaniasis for the foreseeable future, but vaccines have the potential to prevent that 
translating into clinical human disease. 
 
The study is well designed, clearly presented and could be replicated by others with access to the 
biological resources required. Safety is clearly a paramount concern in CHIM, so the choice of 
Leishmania major and its vectors is a wise one that I fully support, this being one of the less 
pathogenic human species, with no known ability to cause visceral disease. However, it is 
important to remember that the various parasite species are not the same as each other, with the 
ability to cause visceral disease (for L. donovani and L. infantum) or mucocutaneous disease (for L. 
braziliensis) being the most important differences. At some stage the question of translation of 
results with L. major to these other species will become relevant, in other words, how well will 
vaccine candidates developed against L. major work against these more dangerous species? CHIM 
with these species will probably never been justified on safety grounds, but what this means is 
that using CHIM that are as faithful to the natural infection process as possible should be an 
ongoing priority, and this is the case with the work described here. 
 
As the authors comment we now know there are many important differences between infection 
by needle inoculation versus infection by sand fly bite. I read the protocol for handling the flies 
with interest and noted that the bites being used with the human volunteers were those from a 
second blood meal, the females having been given a first blood meal of rabbit blood from an 
artificial feeder. Although not directly commented upon, this approach will enable subsequent 
work to be performed where the first blood meal can be seeded with parasites, thus enabling a 
challenge with infected sand fly bite that will be in other respects using flies like those described in 
this study. As mentioned, there are important behavioural differences between uninfected and 
Leishmania-infected sand flies, for example, the latter are much more persistent in their feeding 
behaviour, but still the approach described here should be valid. 
 
There did not appear to be any significant differences between the results using Phlebotomus 
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papatasi and P. duboscqi, but some comment on this would be helpful in the context of future 
work. Although similar in outcome the results of their bites may not be identical, so it would be 
better to work with one species or the other and not to mix and match results when it comes to 
subsequent infection challenge studies, or to include a full comparison as part of those if 
resources allow. 
 
One final comment is that while it is certainly true that the major leishmaniases are known to be 
sand fly transmitted, there is now evidence that one group of Leishmania parasites, those 
belonging to the subgenus Mundinia, may have an alternate vector, biting midges. These insects 
feed and presumably transmit in a very similar way to phlebotomine sand flies, they are both pool 
feeders, so whilst some adjustments may be necessary, the approaches being developed here 
should be largely transferable to this group of parasites.
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